The Discounted Cash Flow (DCF) valuation of Y-mAbs Therapeutics, Inc (YMAB) is (46.63) USD. With the latest stock price at 8.61 USD, the upside of Y-mAbs Therapeutics, Inc based on DCF is -641.6%.
Based on the latest price of 8.61 USD and our DCF valuation, Y-mAbs Therapeutics, Inc (YMAB) is a sell. selling YMAB stocks now will result in a potential gain of 641.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.7% - 6.7% | 5.7% |
| Long-term Growth Rate | 3.0% - 4.5% | 3.7% |
| Fair Price | (368.73) - (24.77) | (46.63) |
| Upside | -4382.6% - -387.7% | -641.6% |